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1. Introduction 
During the past decade, simultaneous pancreas kidney transplantation has been widely 
accepted as the most effective way to achieve normoglycemia in patients with type 1 
diabetes and end-stage renal disease. This procedure was performed for the first time on a 
human in 1966 but it was in the 1980s, with advances in surgical technique and introduction 
of cyclosporine for immunosuppression, that the success rates of SPK became acceptable. 
According to international pancreas transplant (IPTR) report as of December 31, 2004, 23,043 
pancreas transplants were performed worldwide. These included more than 17,000 (17,127) 
performed in the United States (US) and nearly 6,000 (5,916) from outside the US (non-
US). In the US, the majority of the cases, 78% (n=11,898), have been simultaneous pancreas-
kidney transplants (SPK); 16% (n=2427) are pancreas after kidney (PAK) transplants; 7% 
(n=1,008) are pancreas transplants alone (PTA).  
Indications for pancreas transplantation include the development of diabetic complications 
such as ESRD, retinopathy or multiple attacks of hypoglycemic unawareness. 
Unfortunately, pancreas transplantation has been associated with the highest surgical 
complication rate of all the routinely performed organ transplant procedures (except for 
small intestinal or multivisceral transplantation) and the risk of pancreas graft loss from 
surgical complications (technical failures) is higher than from immunological reasons. The 
overall incidence of surgical complications in PTx is reported to be around 10% to 38%. This 
high rate of complications leads US centers to preclude PTA in most centers and now over 
95% of pancreas transplantations are performed in patients with renal disease or a previous 
functioning kidney transplant. One year patient, kidney, and pancreas survival rates for 
recipients of an SPK transplant are 95%, 91%, and 86%, respectively. Compared to patients 
with diabetes who receive a kidney alone, the addition of a pancreas improves long-term 
patient and kidney graft survival. Recipients of a pancreas-after-kidney transplant or a 
pancreas transplant alone have an average 1-year pancreas graft survival rate of 78-83%. 
In this chapter we will thoroughly describe many aspects of this complex transplantation 
procedure including: 
- The history of pancreas transplantation 
- Indications for pancreas transplantation 
- Surgical aspects of pancreas graft procurement from the deceased donor 
- Current surgical techniques for pancreas transplantation 
- Immunosuppressive regimens  
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- Postoperative care of pancreas transplant recipients 
- Complications of pancreas transplantation 
- Long term results of pancreas transplantation  
2. History of pancreas transplantation 
Experimental transplantation of the pancreas in animals began as early as 1890 with proved 
success in the treatment of insulin dependent diabetes mellitus (Burke GW , et al, 2004). 
Grafting 3 pieces of sheep pancreas into the subcutaneous tissue of a diabetic child by 
Williams in 1893 was another attempt to treat diabetes but the patient died after 3 days 
because of severe ketoacidosis (Williams PW, 1903). The first clinical attempt to cure type 1 
diabetes by vascular pancreas transplantation was done simultaneously with kidney 
transplantation, at the University of Minnesota in 1966 three years after first successful 
kidney transplantation (Kelly WD, et al, 1967), but the procedure was not performed with 
any frequency until many years later. Only 12 cases were done between 1967 till 1973 at the 
same center but almost all of them rejected before the first year after the operation. 
Segmental pancreas transplantation from living donors first introduced in 1979. Besides the 
rejection and vascular problems, dealing with pancreas exocrine secretion was complicated 
this type of procedure from the early days. By the mid-70s three different techniques were in 
use: enteric drainage, urinary drainage (into the ureter or directly into the bladder and duct 
injection. Ureteral drainage was first introduced by Gleidman et al (Gleidman et al , 1973). 
Bladder drainage first by direct anastomosis of the pancreatic duct to the bladder by 
Sollinger et al (Sollinger HW, et al, 1984) and then by duodenocystostomy by Nghiem and 
Corry (Nghiem DD & Corry RJ, 1987) was the most common method for exocrine drainage 
during the 1980s and 1990s and was still in use in some centers around the world specially 
for solitary pancreas transplantation. In the early 80's, a dramatic improvement in outcomes 
happened due to introduction of cyclosporine for immunosuppression (Squifflet JP, et al, 
2008). In 1984, Starzl et al (Starzl et al,1984)  reintroduced the technique of enteric drainage 
as originally described by Lillehei which is now is the routine procedure in most pancreas 
transplant centers.  
In 1992, systemic venous drainage which was done through anastomosis of the portal vein 
to recipient iliac veins was replaced by direct portal drainage by Rosenlof et al (Rosenlof 
LK, et al, 1992) and also Shokouh-Amiri et al (Shokouh-Amiri MH, et al, 1992) because of 
its more physiologic pattern of insulin delivery. Now during the modem era of 
immunosuppression, the whole pancreas transplantation technique with portal - enteric 
drainage became the gold standard for simultaneous pancreas and kidney transplantation 
(SPK), and even for pancreas after kidney (PAK) or pancreas transplantation alone (PTA) 
and as of December 31, 2004, 23,043 pancreas transplants were reported to the 
international pancreas transplant registry (IPTR) of whom over 60% were performed in 
the united states. 
3. Indications for pancreas transplantation 
Patients with type 1 or insulin dependent type 2 diabetes mellitus are eligible for pancreas 
transplantation when they have any major complications of their disease, but because of 
complications of this type of surgery and need for lifetime immunosuppression therapy and 
frequent interventional surveillance (such as protocol biopsies), both the clinicians and the 
www.intechopen.com
 Kidney-Pancreas Transplantation 389 
patients should be aware of those conditions that really might benefit from pancreas 
transplantation. Most common indications are as follows: diabetic nephropathy, 
retinopathy, neuropathy, disabling or life threatening hypoglycemic unawareness or 
incapacitating emotional or clinical problems associated with insulin therapy (White et al, 
2009). Some of the rare indications (which are not accepted by all transplant surgeons) are 
diabetic complications after total pancreatectomy, presence of other autoimmune diseases, 
insulin allergy or resistance to subcutaneous insulin.  
Patients should be considered as potential candidate for pancreas transplantation only when 
their morbidity or mortality risk of the surgical procedure or long term immunosuppressive 
treatment are lower than the diabetic complications (Meloche RM, 2007). Unfortunately, 
most patients with chronic diabetes who develop these complications have major 
comorbidities such as obesity, cardiovascular, cerebrovascular or peripheral vascular 
diseases, diabetic gastropathy, and vascular or neuropathic diabetic foot. These patients are 
most suitable for pancreatic islet cell transplantation which is very simpler and has fewer 
and more minor complications that the relatively complex surgical procedure of whole 
pancreas transplantation. 
Patients with diabetic nephropathy who need concomitant renal transplantation are the 
most common eligible patients who benefits from simultaneous kidney pancreas 
transplantation (SPK). Those who previously underwent kidney transplantation are 
candidate for pancreas after kidney (PAK) transplantation. According to 2004 annual IPTR 
report (The University of Minnesota, modified on May 28, 2009, available from 
www.iptr.umn.edu/annual_reports/2004_annual_report/3_txs_cat/home.html) pancreas 
transplant alone  (PTA) now performed in less than 5% of all pancreas transplant recipients 
because unlike SPK or PAK recipients they don’t otherwise need immunosuppression for 
their renal allograft and surgical complications of this procedure and higher rejection rate of 
this type of operation outweigh the potential benefits of glycemic control. PTA is best 
appropriate for those patients with hypoglycemic unawareness, stable renal function, and 
minimum proteinuria (White et al, 2009), because calcineurin inhibitor immunosuppressive 
therapy reduces the glomerular filtration rate at least 20% in the first year after pancreas 
transplantation (Mazur et al, 2004) PAK transplantation is performed mostly in patients who 
have an appropriate living donor for kidney graft and also are simultaneously candidate for 
pancreas transplantation. When coordinate logistics available, these operation using kidney 
graft from the living donor and pancreas graft from a deceased donor may be performed at 
the same time and at the same center. In some centers partial segmental pancreas 
transplantation technique is used for SPK when the living donor is suitable for this complex 
procedure firstly performed by Merkel in 1973 (Merkel et al, 1973). 
The contraindications for pancreas transplantation are the same as other types of 
transplantations (Tiong & Krishnamurthi, 2011): active infections, coronary angiographic 
evidence of significant non-correctable or untreatable coronary artery disease, recent 
myocardial infarction, ejection fraction below 30%, history of recent, incompletely treated 
malignancy (excluding non-melanoma skin cancer), positive HIV serology, positive hepatitis 
B surface antigen serology, substance abuse, major ongoing psychiatric illness, recent 
history of noncompliance, inability to provide informed consent, any systemic illness that 
would severely limit life expectancy or compromise recovery, significant, irreversible 
hepatic or pulmonary dysfunction. In major pancreas transplant centers like University of 
Wisconsin, Minnesota, correctable (by stenting, angioplasty or bypass) coronary artery 
disease is not considered as a contraindication for pancreas transplantation (Sollinger HW, 
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et al, 2009). Most pancreas transplant programs exclude patients older than 45-50 years of 
age, because higher age is an independent risk factor for predicting poorer surgical 
outcome, although the rejection rate is significantly lower in this age group (Gruessner AC 
& Sutherland DE, 2005). 
4. Surgical aspects of pancreas graft procurement from the deceased donor 
Not all deceased donors are suitable for pancreas graft procurement. Absolute 
contraindications for pancreas donation are active infection or malignancy, positive 
serologic evaluation for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV), 
human immunodeficiency virus (HIV), and human T cell lymphotropic virus type 1 (HTLV-
1), proved diabetes mellitus, pancreatitis (acute/chronic), severe pancreatic steatosis or 
edema, previous pancreatic surgery and intra-abdominal sepsis. Donor hyperglycemia is 
common because of stress condition and use of high dose corticosteroids and not a 
contraindication for use of the pancreas, although it may contribute as a minor risk factor for 
long-term graft loss (Gores, et al, 1992). Most surgeons only select younger non-obese 
donors (age 10-50 years, weight 30-100 kg) who are hemodynamically stable without need to 
high doses of vasopressors. Also a cardiocerebrovascular cause of brain death and massive 
volume resuscitation are other risk factors for postoperative complications in the recipients 
(Troppmann C, 2004). Because of these stringent criteria, according to IPTR report, in the 
United States only 21% of the deceased donor pancreata were used for transplantation 
during the year 2004. Because pancreas transplantation is not life saving, procurement of 
other donor organs are more important. If the surgeon considers that the pancreas is not 
suitable for transplantation it may be used for research or pancreas islet cell transplantation 
(Shapiro, et al, 2000).  
The procedure starts with a long midline incision from suprasternal notch to symphysis 
pubis area usually by the liver team. All intrathoracic and abdominal organs are evaluated 
systematically to rule out any suspicious lesion. First, all usual dissections for controlling 
supraceliac and infrarenal aorta, arc of thoracic aorta and superior or inferior mesenteric 
vein should be performed, so in case that patient becomes unstable the surgeon can rapidly 
proceed with cold perfusion of the organs for their safe retrieval. The right colon is 
completely mobilized from retroperitoneum and then an extended Kocher maneuver is 
done.  All ligaments of the liver are transected and then arterial anatomy of the liver and 
pancreas is evaluated by palpating the hepatic artery pulsation in the hepatodudenal 
portion of lesser omentum. The surgeon should have complete knowledge of hepatic artery 
abnormalities and possibility of existence of a right accessory or right replaced hepatic 
artery that originate from superior mesenteric artery. In rare cases the entire hepatic artery 
are originated from superior mesenteric artery. With novel microsurgical techniques none of 
these anomalies is considered as a contraindication for concomitant liver, pancreas or small 
intestinal harvesting from a deceased donor. It’s better to perform a dissection of the 
supraduodenal area to reveal the anatomy of common hepatic artery, gastroduodenal and 
celiac trunk branches specially the origin of the splenic artery. The other dissections may be 
performed after cold perfusion. The common bile duct is divided and infrarenal aorta and 
superior or inferior mesenteric vein are cannulated at the next stage. Supraceliac aorta is 
clamped 3-5 minutes after systemic heparinization and the heart team also clamps the aortic 
arc and cold perfusion is started.  
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The most commonly used solutions for cold perfusion are Belzer University of Wisconsin 
(UW), histidine - tryptophan - ketoglutarate (HTK) and Celsior solution with no significant 
difference in the results when cold ischemia time is less than 12 hours, but UW is the 
standard solution in most centers (Fridell et al, 2010).  
The donor blood evacuated through the supradiaphragmatic or in some certain cases (such 
as history of previous thoracic surgery) infrarenal inferior vena cava (IVC). After removing 
the heart and lungs, liver, pancreas and small intestine usually are procured en bloc and the 
remaining dissection may be performed in the bench procedure. The duodenal lumen is 
irrigated by 500 ml of 20% Betadine, 50 mg/ml amphotericin B and metronidazole solution 
through the nasogastric tube and distal and proximal part are transected by gastrointestinal 
(GIA) staplers. The portal vein is divided 1 cm to 2 cm above the pancreas border. The 
gastroduodenal artery is divided and suture ligated and the splenic artery is divided close to 
its origin and marked by a nonabsorbable 6-0 suture for future identification. The base of 
mesentery at the inferior border of pancreas is transected by another GIA stapler and the 
whole pancreas-duodenum-spleen graft removed.  
In back table or bench procedure, all excessive fat tissue and spleen should be removed and 
the origin of mesentery and all small arterial and venous branches in the inferior border of 
pancreas is reinforced again for future hemostasis. Duodenum is shortened again and 
reinforced in both distal and proximal side by non-absorbable sutures. Arterial 
reconstruction is performed by anastomosis of the donor iliac Y-graft, external and internal 
iliac branches to the graft superior mesenteric and splenic artery, respectively. We also 
recommend using a small segment of donor left gastric or inferior mesenteric artery for 
reperfusion of gastroduodenal artery for better circulation of duodenum and head of 
pancreas to prevent future frequent duodenal ulcers in the graft.  
5. Current surgical techniques for pancreas transplantation 
Forty five years after the first SPK, controversy continues regarding the site of both venous 
effluent and exocrine drainage and also many other aspects in this complex surgical 
procedure. In most centers, SPK is performed separately by two teams. During kidney 
transplant procedure, the pancreas team prepares the pancreas graft for transplantation. 
Usually an intraperitoneal approach is used by a long midline incision and the kidney graft 
is transplanted by standard technique to left  iliac fossa (renal artery to internal or external 
iliac artery and then renal vein to external iliac vein and at last ureter to the bladder or 
native ureter as described in other chapters of this book). Use of right side for pancreas 
transplantation is recommended due to more superficial iliac artery position in this side, 
which makes arterial anastomosis easier. The next step is arterial or venous reconstruction.  
Except for a few minor changes in arterial reconstruction technique (such as reperfusion of 
gastroduodenal artery or changing the site of arterial inflow), there is no significant change 
in the arterial reconstruction technique during these era.  There are at least 2 options for 
venous drainage: systemic or portal drainage. It’s better to reconstruct the venous drainage 
before arterial anastomoses because a short portal vein of the graft may limit the later 
maneuvers needs for venous anastomosis. In our center we use the recipient superior 
mesenteric vein at the base of mesentery below the transverse mesocolon for venous 
outflow(portal drainage) and right common iliac artery for arterial inflow to the donor iliac 
Y-graft. Those surgeons that prefer to use systemic venous drainage use the right external or 
common iliac vein as the venous outflow, perfectly as the same manner that they used 
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external iliac artery and vein for kidney transplantation. After completing the arterial and 
venous anastomoses, the graft is reperfused and complete hemostasis is done. Usually 
despite every effort for complete hemostasis during back table preparing of the pancreas 
graft, there is brisk bleeding around the borders of the graft at the time of reperfusion and 
crystalloid and blood product replacement should be used to prevent hypotension and 
subsequent damage to the kidney and pancreas grafts. Graft splenectomy is done at this 
stage by some surgeons. The next step is anastomosis of the graft duodenum to the recipient 
jejunum (enteric drainage) or bladder (bladder drainage).  When portal drainage is chosen, 
the pancreas head should be directed cephalad and use of bladder drainage is almost 
impossible and vice versa. In other words, if the surgeon selects bladder drainage for duct 
management (as is the case for most PTA surgeries), the pancreas head should be directed 
caudad and use of portal venous drainage won’t be possible. Also if portal drainage is used 
we need a rather longer donor common iliac artery or even an extension graft for arterial 
reconstruction of the graft. 
Drains are inserted at the end of operation around the kidney and pancreas graft separately 
to monitor for postoperative bleeding and leakages. We prefer to perform the kidney 
transplant operation retroperitoneally in the left iliac fossa and at the end use the 
peritoneum to hide the kidney to be able to monitor the kidney graft complications such a 
urine leakage and lymphocele s1eparately from the pancreas graft.  
 It is worthwhile to describe briefly about the evolution of these techniques in the leading 
center of pancreas transplantation in the world, University of Minnesota (Sutherland DE, 
2001). For pancreas graft duct management they used many techniques during this long 
term period: a cutaneous graft duodenostomy, open duct free intraperitoneal drainage, duct 
occlusion (simple ligation or polymer-injection), enteric drainage (ED) and urinary drainage 
(bladder and only 4 cases to the ureter). Except for ED and bladder drainage (BD), the other 
techniques of duct management were used only in the early years of pancreas 
transplantation evolution in a small portion of their cases because of their recognized 
complications and now they (along with most other pancreas centers around the world) lose 
their early enthusiasm to BD technique because of its chronic complications such as 
hyperchloremic metabolic acidosis, dehydration,  chemical cystitis and urethritis, recurrent 
hematuria, bladder stones, and recurrent graft pancreatitis, recurrent urinary tract 
infections, urethral stricture and perineal excoriations (Han DJ & Sutherland DE, 2010). They 
recommended using BD for duct management because they could monitor the graft 
function by serial measurement of urinary amylase and they had showed that decrease in 
urinary amylase always preceded hyperglycemia as a manifestation of rejection in pancreas 
grafts. For SPK bladder drainage transplants, monitoring of urine amylase was less 
important to detect rejection because a serum creatinine elevation usually preceded a urine 
amylase decline when the rejection episode affected both organs. In the past, severe 
complications would lead to conversion of BD to ED in up to 25% of patients within 10 years 
(Sollinger HW, et al, 1992). Enteric drainage also has many complications (at least risk of 
enteric contamination) that may be devastating in case of duodenal necrosis and 
gastrointestinal leakage. 
Several options are available for enteric drainage: side-to-side duodenojejunostomy, or 
duodenojejunostomy with a Roux-en-Y limb and duodenoduodenostomy (Hummel et al, 
2008). The site of duodenojejunostomy (distance from the Treitz ligament) and its length are 
different between authors. Although duodenoduodenostomy complications are more 
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dangerous but endoscopic biopsy and hemostasis of duodenal ulcers of the transplanted 
pancreas-duodenum complex will be made feasible by this technique. 
Systemic venous drainage is technically less demanding and used with less difficulty and 
more frequently by those surgeons who are familiar with kidney transplantation technique. 
In the early days of pancreas transplantation in the University of Minnesota, portal venous 
drainage was used for the pancreas graft venous effluent only in seven cases. Systemic 
hyperinsulinemia caused by systemic drainage first was showed by Diem et al (Diem et al, 
1990). This concept lead Rosenlof et al (Rosenlof LK, et al, 1992) and Shokouh-Amiri et al 
(Shokouh-Amiri MH, et al, 1992) to recommend routine use of portal drainage  for SPK 
transplants in 1992 because of its more physiologic pattern of insulinemia, although the 
carbohydrate metabolism is not different in both groups some authors showed that de-novo 
hyperinsulinemia predisposes to accelerated atherosclerosis (Fontbonne A, et al, 19991) and 
increasing the level of low density lipoprotein( LDL) (Hughes TA , et al, 1995) but its 
relevance to pancreas transplant recipients is not certain.  
Some centers now use extra- or retroperitoneal approaches for better accessibility of the 
pancreas graft for postoperative routine percutaneous biopsies and easier arterial 
anastomosis and some of them suggest using an en bloc kidney-pancreas transplantation 
from the same donor. The technique of retroperitoneal pancreas transplantation with portal-
enteric drainage was first described by Boggi et al in 2005 (Boggi et al, 2005). This method 
may be used in patient with severe intraperitoneal adhesions due to multiple previous 
abdominal surgeries and also for pancreas retransplant. Kahn et al described the same 
technique by systemic venous drainage (Kahn et al, 2008). They recommend this approach 
in obese patient with severe iliac artery atherosclerosis because of best exposure of the aorta 
and inferior vena cava by this method. In the en bloc techniques donor pancreas and left (or 
right kidney) is harvested en bloc in line with abdominal aorta so that the superior 
mesenteric, celiac artery and renal artery origins are maintained intact on the aorta and no 
arterial reconstruction by donor iliac artery would be needed in the back table procedure. 
Then the aorta could be used as the complex graft inflow conduit. Portal vein and renal vein 
may be anastomosed separately  (Schenker P, et al, 2009) but we recommend to anastomose 
the graft portal vein to the left renal vein in the bench procedure, and then use the graft 
renal vein as the venous outflow of the graft. This will reduce the warm ischemia time by 
reducing the number of vascular dissections and anastomoses.  
6. Immunosuppressive regimens  
Unlike other solid organ transplantations, pancreas transplantation needs 
immunosupression for prevention of alloimmune rejection or autoimmune recurrence of 
diabetes mellitus even in transplant between identical twins (Sutherland DE, et al, 1984). In 
the early years of pancreas transplantation, only azathioprine and prednisone were used for 
immunosupression, but such a regimen was not adequate for prevention of rejection in PTA 
recipients (Sutherland et al, 2001).  In the later years Minnesota antilymphocyte globulin 
added to this regimen for induction and maintenance immunosupression evolved to triple 
therapy by cyclosporine, azathioprine and prednisone. This change along with better 
surgical methods and better preservation of the deceased donor pancreas by UW solution 
resulted in better long term results of pancreas transplantation during the era of late 80’s 
and early 90’s. The pancreas rejection rate remained as high as 78% in this era (Stegall  MD, 
et al, 1997). Gradually, cyclosporine and azathioprine were replaced by Tacrolimus 
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(Prograf™) and Mycophenolate mofetil (MMF, Cellcept™) during the later years and 
monoclonal anti T cell antibodies such as basiliximab and daclizumab added to induction 
immunosuppressive regimen of these patients. By use of these new regimens, risk of 
rejection decreased to less than 8-11% in the modern era of pancreas transplantation 
(Cantarovich D & Vistoli F, 2009).   
The routine immunosupression regimen in most pancreas transplant centers includes a T 
cell depleting agent such as rabbit antithymocyte globulin (rATG or Thymoglobulin™) with 
a total dose of 4-12 mg/kg in divided doses, or alemtuzumab (Campath™) or an 
interleukin-2 receptor antagonist such as basiliximab (Simulect™) or daclizumab 
(Zenapax™) for induction immunosupression. We add a low dose intravenous 
methylprednisolone (Solumedrol™) in the day of operation to prevent allergic reactions to 
these agents. Unfortunately, these induction regimens only reduce the biopsy proven acute 
rejection (BPAR) episodes, but had no or modest effect on the patient or graft long term 
survival (Sutherland DE, 2009). Information about use of anti inter leukin-2 receptor 
antibodies are confounding. For example, Becker et al. found no significant differences in 
patient and graft survival comparing the outcomes of no induction versus daclizumab or 
basiliximab in 63 SPK transplant recipients receiving tacrolimus, MMF and prednisone. 
There was, however, a slightly higher rate of deaths due to sepsis in the anti-IL-2R induction 
group (Becker et al, 2006). Newer data mostly agree with the use of alemtuzumab for 
induction immunosuppression, without incurring a risk of increased infections or 
malignancies except for cytomegalovirus. (Sollinger et al, 2011) . A new randomized trial has 
showed that in the short term follow-up after SPK, alemtuzumab and rATG induction 
therapies has been similarly safe and effective but alemtuzumab is more cost-effective and 
has been associated with less BPAR episodes (Farney AC, et al, 2009). 
 For maintenance immunosupression, perhaps the best current regimen is prednisolone free 
or rapidly steroid tapering regimens which consist of tacrolimus and MMF combinations. 
Omitting the steroids from the maintenance regimens results in better wound healing and 
also prevents from steroid induced insulin resistance. Replacing the MMF with sirolimus 
has no effect on pancreas rejection rates, but had poorer long term kidney graft survival in 
the SPK recipients, because sirolimus accentuates the nephrotoxicity of tacrolimus (Gallon 
LG, et al, 2007). Tacrolimus per se had diabetogenic effects in other solid organ transplant 
recipients, but such an effect has not been shown in pancreas transplant recipients, may be 
due to more cautious use of this nephrotoxic drug in SPK recipients or use of healthier 
donors for pancreas transplantation (Ming CS & Chen ZH, 2007). Because of known 
nephrotoxicity of calcineurin inhibitors (CNIs) e.g. tacrolimus or cyclosporine, avoidance of 
these drugs in all pancreas transplant recipients who are potentially at risk of renal damage 
(SPK or PAK recipients) or future renal failure (PTA recipients) is desirable but all initial 
attempts with calcineurin inhibitor avoidance or minimization are less promising (Singh RP 
& Stratta RJ, 2008). Although newer agents such as sirolimus, everolimus, and CTLA-4 Ig 
are agents known to be either both nonnephrotoxic and nondiabetogenic or less so when 
compared with CNIs, but their impact on pancreas transplant results are not yet evaluated 
by randomized trials and their solitary use may be dangerous for the recipients and end up 
with graft loss (Cantarovich D & Vistoli F, 2009). 
7. Postoperative care of pancreas transplant recipients 
Perioperative care of pancreas transplant patients has no difference with any other major 
operation in diabetic patients. Kidney-pancreas recipients should be dilysed briefly for 1-2 
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hours before the operation to maintain the serum potassium below 5.5 meq/l and also to 
optimize the platelet function. Complete fluid removal is unnecessary. During the operation 
all of these patients need routine anesthesiologist monitoring with special attention to 
hemodynamic stability, tight control of blood sugar (to prevent both hypo- or 
hyperglycemia) and serum potassium, arterial blood gas and prevention of volume overload 
by keeping central venous pressure (CVP) around 8-10 mmHg. Ketoacidosis may be occur 
and should be prevented by intravenous insulin infusion if required. Sterile aseptic 
techniques are recommended for all venous and arterial line placements. 
 In kidney-pancreas recipients, usually kidney transplantation is done before the pancreas 
operation. During the kidney operation the patient is kept mildly volume expanded and 
before declamping the renal vasculature, the systolic blood pressure should be around 120 
mmHg and Mannitol and furosemide should be infused as described in the other chapters 
of this book. Induction immunosuppressant (methylprednisolone or any types of t-cell 
receptor or interleukin-2 antibodies) usually started preoperatively and continued 
throughout the operation. Some surgeons advise to use these agents prior to declamping of 
vascular anastomoses.  
After completion of kidney transplantation, the anesthesiologist should carefully monitor 
the brisk urine output and maintain it at least around 4 ml/kg/hour with appropriate fluid 
and electrolyte management throughout the remaining of the operation. Hypovolemia leads 
to acute tubular necrosis (ATN) of the renal allograft and volume overload will result in 
bowel and pancreas graft edema and may lead to postoperative abdominal compartment 
syndrome and graft dysfunction. Anticoagulation is not recommended for general kidney 
transplant alone recipients unless in the instance of presence of any other indications like 
mechanical heart valve or history of coagulopathy.  But because pancreas is a low blood 
flow organ, especially when portal drainage is chosen as the preferred method for surgery, 
before clamping of the inflow veins or arteries, it’s better to use systemic heparinization of 
the patient and we prefer to continue intravenous heparin postoperatively at least for 5 days 
to maintain the activated partial thromboplastin time (aPTT) around 1.5 times the normal 
value (between 55 – 85 seconds) to prevent graft vascular thrombosis. 
After the operation the patient is transferred to transplant intensive care unit and CVP, vital 
signs, arterial blood gas, blood pressure, urine output and blood glucose are monitored 
continuously. Almost all patients are extubated in the operating room and don’t need 
postoperative mechanical ventilation.  
Kidney transplant patients usually have large urine outputs (as much as 20 liters/day) that 
should be replaced according to the patient fluid and electrolyte condition as discussed in 
the other chapters. Hypotension is usually due to intraabdominal bleeding (even in the 
absence of drainage from abdominal drains) or gastrointestinal bleeding from duodenal 
anastomosis and should be treated emergently by reexploration of the patient and fluid 
management. Hypertension should be avoided and treated appropriately to prevent 
bleeding and graft malfunction.  
Oral immunosuppressive drugs (usually tacrolimus and MMF) are started after the day of 
operation. Prednisolone replaces intravenous methylprednisolone after 3 days by a dose of 
0.5-1 mg/kg/day, but rapidly tapered to near zero during the next 4 weeks-3 months. All 
patients should receive prophylactic broad spectrum antibiotics for 2-5 days and most 
centers add antifungal drugs (such as amphotericin B or an azole derivative or caspofungin) 
and anti cytomegalovirus (CMV) drugs (e.g. gancyclovir) to this regimen. These protocols 
are different slightly among pancreas transplant centers and its better and mandatory that 
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each physician follow the routines of her/his center to avoid and confusion in the patients 
and personnel and future evaluations of the center. During the first 24 hours the patient may 
need small doses of intravenous insulin for maintaining the blood sugar below the 200 
mg/dl because of delayed graft function or use of high doses of corticosteroids but after that 
or in case of any unusual increase in the serum glucose level, prompt assessment of graft 
vascular status by Duplex ultrasound and appropriate intervention should be done 
emergently. We routinely monitor the graft vasculature by Duplex ultrasound at least every 
12 hours for 5 days after the operation. Many other means are available for continuous 
monitoring of graft function besides the blood sugar and duplex scanning. Serial 
measurements of serum amylase and/or lipase, C-peptide, and urine amylase and protocol 
ultrasonographic or computerized scan (CT) guided biopsies are among them (Han DJ & 
Sutherland DE, 2010).  
Drains should be monitored for unusual leakage or bleeding and removed as soon as 
possible (usually after 5 days for pancreas drains and 24 after removing the Foley catheter 
for perirenal drain). Nasogastric tube remains until the return of gastrointestinal function 
usually for at least 72 hours. A recent study has showed that omission of a nasogastric tube 
has been associated with earlier return of bowel function, less discomfort, and shorter length 
of stay (Barth RN, 2008). Ambulation of the patient is desirable in the first 24 hours after the 
operation to prevent deep vein thrombosis and also other known complications of 
bedridden patients such as atelectasis or postoperative ileus. 
8. Complications of pancreas transplantation 
Despite large improvements in immunosuppression and surgical techniques, the history of 
pancreas transplantation, unlike that of other abdominal organ transplants, has largely been 
shaped by its associated complications (Troppmann C, 2010). We can discuss about these 
complications in 3 distinct categories: surgical, infectious, immunologic and other non-
immunologic. Infectious complications are not specific for pancreas transplantation and 
many of their aspects are in common with other solid abdominal organ transplantation and 
discussion about them is presented in other chapters of this book.  
Surgical complications 
Surgical complications now decreased to at least 8% in large series reported by experienced 
pancreas transplant center s around the world and most of them frequently result in graft 
loss and increase recipient morbidity and mortality significantly and augment transplant 
cost considerably (Goodman J & Becker YT, 2009). Many of the surgical complications (such 
as hematuria, duodenocystostomy leakage, reflux pancreatitis, etc) are unique to the bladder 
drainage as previously discussed. These known complications lead pancreas transplant 
centers to avoid from bladder drainage and use this technique only for PTA cases. Over 25% 
of these cases require conversion of BD to ED. 
Vascular thrombosis 
Vascular thrombosis has remained the most common complication of pancreas transplant 
procedure with a frequency of 3-10% (Gruessner AC & Sutherland DE, 2009). Other major 
complications include: intraabdominal bleeding, gastrointestinal bleeding, leakage (from 
duodenal anastomosis), pancreatitis, pancreatic necrosis, pancreatic fistula, abscess 
formation and other complications of any other major abdominal surgery such as atelectasis, 
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pneumonia, deep vein thrombosis, wound infection, dehiscence, and cardiovascular 
problem which is common in diabetic and chronic renal failure patients. 
Graft vascular thrombosis has many factors that most of them are technical because of 
several vascular anastomoses that needs for pancreas transplantation. Rotation during 
arterial reconstruction at the time of back table preparing, inadvertent intimal damage to the 
iliac artery Y-graft during harvesting and over inflation of the arteries during flushing are 
the known causes of arterial thrombosis. Higher donor age, cardiocerebrovascular cause of 
brain death and massive fluid resuscitation and hemodynamic instability of the donor and 
use of HTK as the preservation solution, especially when cold ischemia time is over 12 
hours, and recipient hypercoagulable states or use of sirolimus are other important factors 
(Troppmann C, 2010). Venous thrombosis may be secondary to arterial thrombosis, severe 
pancreas rejection, and severe graft pancreatitis or may be completely technical or due to 
use of venous extension graft. There is no difference in the rate of graft thrombosis 
according to the venous drainage (systemic or portal) technique. Also PAK transplantation 
has been an independent risk factor for graft vascular thrombosis (Troppmann C, et al, 
1996). Most centers use systemic heparinization for prevention of vascular thrombosis and 
continue this treatment for 5-7 days and after that change this regimen to 325 mg/day acetyl 
salicylic acid (ASA) or warfarin for selected cases (second transplants or confirmed 
hypercoagulable state), although some authors hadn’t agree with this concept in the past 
(Sollinger HW, 1996). Usually the first sign of graft thrombosis is increasing the blood sugar 
level that should be promptly assessed by Duplex ultrasound.  The patient may complain 
from abdominal pain and later abdominal tenderness will be revealed. Venous thrombosis 
will results in dark hematuric urine if bladder drainage had been used. Except for a few case 
reports most of these cases needs relaparotomy for graft removal, but if diagnosed early 
interventional radiologists or reanastomosis may be very rarely salvage the graft.  
Leakage  
Leakage from duodenojejunostomy or duodenoduodenostomy is a devastating 
complication of pancreas transplantation that may be associated with high morbidity and 
mortality, if recognized late. Because of spillage of enteric content, the patients develop 
signs and symptoms of peritonitis such as abdominal pain and tenderness, fever, high 
leukocytosis, and bilious content in abdominal drains. Sometimes this leakage is minor and 
the site of leakage contained by the greater omentum. Using broad spectrum antibiotics and 
Roux-en-Y reconstruction help more to obscuring the symptoms. In this situation, signs and 
symptoms may be obscure and only developing ileus, low grade fever, tachycardia and 
tachypnea, mild hyperglycemia, hyperamylasemia, low platelet count, will lead the surgeon 
to perform additional imaging studies (mostly abdominal CT scan) to diagnose this 
problem. The patient should be undergone exploration and in most cases the best option is 
graft pancreatectomy if peritonitis is diffuse or associated by multiple intraabdominal 
abscesses, or the patient ids unstable. Leakage from bladder drained pancreas may have 
milder symptoms and treated by combined bladder decompression and percutaneous 
drainage or conversion to enteric drainage. In cases of severe sepsis or diffuse infection, 
graft pancreatectomy is inevitable. Obscure leakages may be revealed as late as 2 weeks 
after the operation by abdominal abscess or pancreatic fistula that may be treated 
conservatively by percutaneous drainage, but many times the patient will prefer the graft to 
be removed because of the associated bothering complications such as skin excoriations by 
pancreas secretions. Also, pancreas fistula may be a complication of focal necrosis (due to 
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ischemia, rejection or infection) of the pancreas graft which communicate with the 
pancreatic duct or a complication of graft pancreatitis.   
Many factors is contributed to anastomosis leakage, including technical errors, ischemia of 
the head of pancreas (due to vascular events, previous atherosclerosis of the donor, 
edematous duodenum at the time of reconstruction), reexploration for another causes, 
intraabdominal bleeding or diffuse primary peritonitis, severe acute rejections, and CMV 
infections. Some surgeons suggest that revascularization of the gastroduodenal artery or 
even the gastroepiploic artery may prevent ischemia of the head of pancreas and the 
duodenal C-loop (Nghiem DD, 2008 and Muthusamy ASR et al, 2008). We use this 
technique in every patient that the gastroduodenal artery is relatively large. This may also 
protect the duodenum from later ulcers and bleeding. 
Pancreatitis 
There is no uniformly accepted definition for graft pancreatitis, but all of the available 
definitions include the signs and symptoms of native pancreatitis with rising lipase and 
amylase, and maintained endocrine function (Troppmann C, 2010). Unfortunately these 
serum markers associated poorly with graft pancreatitis and may be prolong elevated after 
pancreas transplantation. Early pancreatitis is the result of poor graft handling, long 
ischemia time and preservation and reperfusion injury and may be visible during the 
operation, by graft edema and diffuse or focal fat necrosis around the graft. Prolonged cold 
ischemia time over 12 hours, use of HTK as the preservation solution and also poor donor 
quality are other risk factors (Han DJ & Sutherland DE, 2010).  In case of bladder drained 
pancreas, pancreatitis may be the result of urine reflux. Most of these conditions are self 
limiting and adding the subcutaneous octreotide (0.1-0.2 mg every 8 hours) for 3-5 days 
after the operation, bowel rest and temporary total parenteral nutrition is the only treatment 
that needed. In rare cases it is so severe that the only option for treatment will be graft 
necrosectomy or pancreatectomy. In BD drained cases, the best treatment for resistant cases 
is conversion to enteric drainage. Rarely the cause of acute pancreatitis in these patients is 
CMV or other viral infections that if confirmed should be treated by gancyclovir or other 
antiviral agents. 
Graft pancreatitis may be complicated just like the native pancreatitis with infections, 
pseudocysts, peripancreatic sterile fluid or pancreatic ascites, pancreatic fistula, and arterial 
or venous thrombosis or bleeding which should be treated accordingly.  
Bleeding 
Intraabdominal bleeding is relatively common after this operation. In most cases this is a 
technical error due to poor hemostasis of the pancreatic graft or the so many vascular 
anastomoses that used. Sometimes it is due to technical errors in the associated kidney 
transplant procedure. It may be due to heparin overdose that should be diagnosed by 
measurement of aPTT and if needs treated by protamine sulfate. Severe graft pancreatitis or 
pseudoaneurysms of the infected vascular anastomoses are another source of late abdominal 
bleedings in these patients that may be delayed as long as 2 weeks to several months after 
the operation.  Early postoperative hypertension may cause transient bleeding from vascular 
anastomoses and through the abdominal drains that will be stopped spontaneously when 
the hypertension controlled appropriately with any need to reexploration.    
Gastrointestinal bleeding is unique complication of enteric drainage. The site of bleeding 
may be duodenojejunostomy, distal jejunojejunostomy of the Roux-en-Y loop, 
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duodenoduodenostomy (DD) or mucosal ulcers in the graft duodenal C-loop (Nikeghbalian 
S, 2009) due to ischemia, rejection or CMV infection. One should rule out other sources of 
bleeding, such as native small bowel CMV infections, stress native gastric or duodenal 
ulcers by upper GI endoscopy or enteroscopy and also obscure site of bleeding such as 
neoplasm or angiodyplasia of the colon. If DD had been used for enteric drainage, 
endoscopy can be used for diagnosis and treatment. In other cases, angiography, red blood 
cell isotope scan, or enteroscopy may be used for diagnosis, but in most cases at last the best 
option is to explore the patient (Orsenigo E, et al, 2005).  
Lymphocele and chylous ascites 
Because of diverse perivascular dissections (around the aorta, IVC, superior mesenteric vein 
and iliac arteries and veins) in pancreas transplantation surgery, intraabdominal or perigraft 
sterile collections due to lymphorrehea are common. These collections may be so much that 
exit through the abdominal drains and when the patient returns on oral diet being frankly 
chylous. Perigraft collections are one of the causes of graft dysfunction and should be drains 
percutaneously. Chylous ascites is usually self-limiting and therapy is only supportive 
(replacing the fluid and electrolytes and use of oral short chain fatty acids and removing the 
drains to prevent lymphocyte and protein depletion. The best treatment is prevention by 
meticulous dissections and ligation of all perivascular lymphatics during the dissections.           
Immunologic complications 
Acute rejection 
Rejection of the pancreas graft is as much as 40 % in the past and pancreas transplant 
recipients receive the highest level of immunosuppressant drugs among other abdominal 
organ transplantations. One-year rates of rejection have steadily decreased and are currently 
in the 10–20% range depending on case mix and immunosuppressive regimen (Singh RP 
&Strata RJ, 2008). The highest rate of graft loss due to immunologic rejection is seen in PTA 
recipients and the lowest incidence is in SPK patients, probably due to immunologic 
protective effect of the renal graft or earlier diagnosis of the rejections with better response 
to therapy. In the era that BD pancreas transplant was a routine the best indicators of 
pancreas transplant rejection was decreasing urine amylase and lipase which was preceded 
by hyperglycemia. In other words, BD experience showed that pancreas exocrine function is 
affected sooner that its endocrine function and when hyperglycemia presents it would be 
too late to salvage the pancreas from acute rejection.  In the SPK patient, increasing the 
serum creatinine due to rejection usually preceded the hyperglycemia, and then diagnosis of 
the renal graft rejection actually means the pancreas rejection as well and both can treated 
simultaneously by the same antirejection treatment except for rare instances. Nowadays, 
with increasing experience, protocol percutaneous pancreas biopsies are routine procedure 
in the armamentarium of any major pancreas transplant unit. By these timely scheduled 
biopsies, every pancreas rejection could be diagnosed before its clinical and paraclinical 
symptoms present but until now the controversies continued about the candidates and 
interval of this time of protocol biopsies for the surveillance of pancreas graft rejection 
(Gaber LW, 2007).     
It’s shown that HLA mismatch is a major contributor to pancreas rejection and fully HLA 
matched recipients has the lowest levels of rejections when on the same immunosuppressive 
protocol (Burke, et al, 2004).  Other series showed that combination immunosuppressive 
therapy including T-cell depleting antibodies for induction, tacrolimus and MMF could 
improve the outcome significantly, even in poorly HLA matched PTA recipients (Gruber 
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SA, et al, 2000). However, in the PTA and PAK categories, HLA matching has remained an 
important outcome factor (Han DJ & Sutherland DE, 2010). 
Signs and symptoms of pancreas rejection are obscure. Only 5-20% of patients developed 
mild fever, abdominal pain or distension or sometimes ileus or diarrhea (Sutherland DE, et 
al, 2010). The clinicians should be rely on paraclinical markers and after performing the 
biopsy the best approach is to treat empirically when a combination of paraclinical changes 
support existence of an acute rejection episode, if the results of the biopsy prepare with 
delay. The best treatment for confirmed acute rejection episodes is the use of pulse 
methylprednisolone therapy plus increasing the dose of oral drugs or adding the sirolimus 
to the previous drugs. Nephrotoxicity and diabetogenic effect of tacrolimus, and effect of 
corticosteroids on insulin resistance induction should be in mind. In severe cases use of 
thymoglobulin or other T-cell depleting antibodies may be required. As previously 
described many immunosuppressive protocol are under investigation now to better prevent 
these acute rejection episodes which most of them focused on corticosteroid spring and also 
use of T-cell depleting antibodies for induction.   
Chronic rejection 
Previously, chronic rejection does not appear to be as large a problem for pancreas-
transplant recipients as it does for renal-transplant recipients (Hopt UT & Drognitz O, 2000). 
As the number of pancreas transplants surviving beyond the first year increases, chronic 
rejection is becoming increasingly common (Burke, et al, 2004). The rate of pancreas loss to 
chronic rejection was 8.8% in 914 pancreas transplants followed for 3 years. Chronic 
rejection was highest in the PAK (11.6%) and PTA (11.3%) and lowest for SPK (3.7%)( 
Humar A ,et al, 2003). The most important pathologic changes in chronic rejection are 
replacing the pancreas tissue with fibrous band with distortion of architecture and loss of 
acini (Gaber LW, 2007). The severity of chronic rejection is not correlated well to the graft 
loss, but clinically the patients become hyperglycemic, first with response to oral 
hypoglycemic agents and then low dose insulin injection an at last completely depend on 
insulin injection for the rest of their lives.  There’s no definite treatment for this type of 
rejection, which may be simply a non-immunologic “physiologic wear and tear “of the 
organ, but some authors try to use sirolimus in these conditions (Matias P, et al 2008).  
Non-immunologic complications 
One the known complications of every solid organ transplant is primary nonfunction or 
delayed graft function. Primary non-function is a definition of inclusion. No other cause of 
graft nonfunction should be found, e.g. graft vascular thrombosis, graft necrosis, or severe 
acute rejections or pancreatitis. In this condition the graft is viable and non-inflamed with no 
need for pancreatectomy, but no insulin secretion is found and the patient needs insulin 
injection as his/she preoperative situation. Some patients transiently need low doses of 
insulin for their blood glucose hemostasis, but after a maximum of 1 week this requirement 
decreased to zero. This condition is named “delayed graft function”. In both of this 
condition no frank anatomic or pathologic changes in the graft is found in the postoperative 
assessment of the patient. Poor donor quality and poor handling of the graft is the only 
causes that may contribute to these conditions.  
Other non surgical and non-immunologic complications also may be seen in these diabetic 
patients. Many of these are due to preoperative diabetic complications. Delayed gastric 
emptying (gastroparesis), constipation or diarrhea, dizziness and lightheadedness (all due to 
autonomic neuropathy), peripheral neuropathy, poor visual acuity (accelerated 
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retinopathy)and accelerated cataract are among these complications. Many of these diabetic 
signs and symptoms are multifactorial and side effects of the immunosuppressant drugs 
and multiple other antifungals and antivirals that used for these patients plus preoperative 
poor diabetic control accelerates them. Every effort should be used to diagnose the treatable 
causes and treat them accordingly. For example for diabetic gastroparesis, use of 
erythromycin or domeperidone has been moderately successful (Zaman f, et al, 2004).  
Intractable diarrhea may be due to CMV or other microbial or protozoal infections which 
should be treated. But when no known cause is found, the best treatment is dividing the 
dose o MMF to 4 times a day and also use of subcutaneous octreotide. Also every transplant 
team member should be completely remember the common complications of the 
immunosuppressive drugs and treat them appropriately or change the drugs if possible. 
9. Long term results of pancreas transplantation  
Long term results of pancreas transplantation improve day by day with better surgical 
experience and use of more potent immunosuppressive regimen. Pancreas graft 1 year 
survival rate improves from 75% in 1998 to 85% at the end of 2003 for SPK cases, and from 
55 to 77% for PAK and from 45 to 77% in PTA patients (Gruessner AC & Sutherland DE, 
2005).  This improvement also is seen in PTA patients that traditionally have the worst 
outcome, as shows in many studies. For example in a report Stratta et al. by 1 year patient 
and graft survival has increased to 96% and 86%, respectively (Stratta RJ, et al, 2003).  In one 
the largest recently published studies, the 5-year, 10-year, and 20-year patient survival for 
SPK recipients was 89, 80, and 58%, respectively (Wai PY & Sollinger HW, 2011). 
Now, by decreasing the technical failures, the randomized studies to valuate other effective 
factors can be performed with better accuracy and less confounding bias. Perhaps the best 
statistics that show the effect of pancreas transplantation is the statistics about comparing 
the patient survival in kidney transplant alone recipients with SPK patients. Even in older 
studies, life expectancy of younger recipients (less than 50 years) of SPK is 10 years longer 
than diabetic patients who only received a kidney graft from deceased donors (23.4 years vs 
12.9 years) (Tyden G, et al, 1999, Ojo AO,etal, 2001). When both grafts were procured from 
deceased donors, SPK transplant recipients has better survival rate than kidney transplant 
alone (KTA) recipients but this difference is not significant when KTA patients received 
their grafts from living donors. The presence of a functioning pancreas graft improved 
survival by 20% at 8 years (Reddy KS, 2003).  
Patient survival is not statistically different according to the type of exocrine drainage (BD 
vs. ED), but quality of life is better and overall complications is less when BD is used 
(Sollinger HW, et al, 2009). Despite the improved survival, the most common type of death 
in these patients is death with a functioning graft and cardiovascular morbidity remains a 
major contributor to patient outcome in these patients (Sollinger HW, et al, 2009). 
Comparing with KTA recipients, quality of life in those 95% of patient who survive after 
SPK transplantation is improved significantly, due to cessation of insulin injections, multiple 
needling for glucose monitoring and better emotional status (Sutherland De, et al, 2001 & 
Joseph JT, et al, 2003).  
Effect on end organ damage 
Pancreas transplantation improves glycemic control in long term follow up, manifested by 
lower hemoglobin A1C level, improved lipid profile and insulin mediated protein kinetics, 
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normal hepatic glucose production and counter-regulatory effects of glucagon to 
hypoglycemia (White SA, et al, 2009). 
Sollinger et al suggests that despite numerous reports of improvement in secondary diabetic 
complications after SPK, retinopathy and cardiac or vascular complications of diabetes are 
not reversible and show no improvements after SPK, but severe (peripheral and autonomic) 
neuropathy is an exception to this rule (Sollinger et al, 2009). Diabetic retinopathy will 
deteriorate after pancreas transplantation in over 30% of patients if it is in an advanced 
proliferative phase prior to the operation, but after 3 years the pancreas transplantation 
results in stabilization of retinopathy progression (Chow VC, et al, 1999). Cataract is a 
known complication of any organ transplantation and is the results of corticosteroids and 
calcineurin inhibitors and may become evident after pancreas transplantation as well. 
Macrovascular effects of diabetes may not improve after pancreas transplantation, especially 
because of calcineurin inhibitor (CNI) effect on weight gain, dyslipidemia and hypertension, 
and many other risk factors that are very common in diabetic patients. Also the peripheral 
vascular disease in diabetics is often far too advanced to reverse. Because, most centers 
exclude patient with Macrovascular diabetes complications and no conclusive study exists 
about effect of pancreas transplantation on natural history of macrovascular disease in these 
patients (Sutherland De, et al, 2001). Deterioration depends on the ongoing risks. Some 
centers show the benefits of pancreas transplantation on cerebrovascular system, but again 
the results are inconclusive. Coronary artery disease, diastolic function, left ventricular 
geometry and cardiac autonomic function may be improved after SPK comparing with KTA 
recipients after a few years (White SA et al, 2009).  
Normoglycemia also improves the diabetic glumerulopathy (but does not reverse it) and 
decrease the proteinuria. On the other hand, use of CNIs per results in nephropathy and 
may decrease the creatinine clearance. SPK recipients may not survive enough to benefit 
from the effects of normoglycemia on their nephropathy. In diabetic KTA recipients, the 
diabetic nephropathy is progressively leading to lower kidney graft survival and many 
studies show that PAK transplantation may improves the kidney graft survival by 
prevention of accelerated diabetic glumerulopathy in these patients. ). Some studies shows 
that PTA (if done early enough) can preserve renal function, but It takes at least 5 years until 
a pancreas transplant can reverse the lesions of diabetic nephropathy (Sutherland De, et al, 
2001).    
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